PLENARY SPEAKER

Reimagining Medicine to Bring New Therapies for our Patients

Vas Narasimhan, MD, MPP

CEO, Novartis

Basel, Switzerland

Manipulating the Microenvironment for AML Therapies (GMI 1271)

Daniel J. DeAngelo, MD, PhD

Chief, Division of Leukemia,

Dana Farber Cancer Institute

Professor of Medicine,

Harvard Medical School

Update in CAR-T and Other Cell Therapies for AML

Gail J. Roboz, MD

Professor of Medicine & Director

Clinical Translational Leukemia Program

Weill Medical College, Cornell University

FDA Perspective on New Therapy Development for AML

Lori A. Ehrlich, MD, PhD

Medical Officer, DHHS/CDER

Food and Drug Administration (FDA)

Immunomodulatory Therapeutic Strategies (PD1/PDL1, CD47, CD70)

David Sallman, MD

Assistant Member

Department of Malignant Hematology

Moffitt Cancer Center & Research Institute

Precision Medicine for Pediatric Acute Myeloid Leukemia

Yana Pikman, MD

Assistant Professor of Pediatrics, Harvard Medical School

Attending Physician, Pediatric Oncology, Dana-Farber Cancer Institute

From Disney to Doxorubicin: Childhood Cancer Perspective from a Medical Dad

Andrew J. Herber, PA-C

Mayo Clinic Hospital

SARS-CoV-2 Infections in Malignancy

Vivek Naranbhai, MD, PhD

Clinical Fellow in Medicine

Dana Farber Cancer Institute

Updates in MDS Treatment

Andrew M. Brunner, MD

Asst. Professor, Harvard Medical School

Assistant, Center for Leukemia

Massachusetts General Hospital

Transplant in the Context of MDS Patients

Corey Cutler, MD, MPH, FRCPC

Medical Director, Adult Stem Cell Transplantation Program

Director Clinical Research, Stem Cell Transplantation

Associate Professor of Medicine, Harvard Medical School

NK Cell Therapies for AML

Rizwan Romee, MD

Director, Haploidentical Donor Transplantation Program, Associate Professor of Medicine, Harvard Medical School, DFCI